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2013; Cakmak and Rosen, 2013).
In addition the success of using GnRH antagonist during the preced-
ing luteal phase of stimulation cycle was shown resulting in a rapid fall
of progesterone (Anderson et al., 1999).
In this case series study we aimed to evaluate stimulation outcome
following conventional start or random-start controlled ovarian stimu-
lation in gynecologic cancer women.
Materials and methods
This prospective study was performed at a tertiary referral universi-
ty hospital from January 2013 to February 2014, and was approved byIntroduction
Increasing survival rates in patients who suffer from oncological
disease and improvement in reproductive medicine techniques have
led to increasing use of different fertility preservation methods.
Controlled ovarian stimulation (COS) for mature oocyte cryopreserva-
tion or embryo cryopreservation has highest success rates compared
with other technologies, therefore it is considered the preferredmethod
for fertility preservation in cancer patients (American Cancer Society.
Cancer facts and ﬁgs., 2012). Most cancer patients are treated with a
GnRH antagonist-based protocol since this protocol provides the
shortest delay of the cancer treatment and the lowest risk of impending
ovarian hyperstimulation syndrome (OHSS) by induction of ovulation
with GnRH agonist (McLaren and Bates, 2012).
Conventionally, ovarian stimulation for oocyte/embryo cryopreser-
vation with GnRH antagonist is initiated at the beginning of the follicu-
lar phase. This stimulation protocol may require 2–6 weeks, depending
on the patient's menstrual cycle day. Due to the urgent need of medical
or surgical intervention in patients with known malignancies, antago-
nist protocols with random start COS have been proposed (Quinn
et al., 2008; Signorello et al., 2010). This approach was designed to
provide the shortest time for oocyte collection and claimed to be asalth Research Center, Vali-e-Asr
+98 21 66581658.
ail.com (B.H. Rashidi).
. This is an open access article underThe Institutional Review Board and Ethical Committee of the hospital.
A written informed consent was obtained from all participants at the
ﬁrst visit. All patients were recently diagnosed with cancer and were
planned to receive treatments (surgical or non surgical) which could
lead to a signiﬁcant chance of disruption to their ovarian function and
therefore referred for counseling for fertility preservation methods.
Patients were evaluated for fertility preservation within 48 h. Time
frame until the initiation of cancer treatment was at least 2 weeks.
The decision to perform with a conventional versus a random-start
COS was elected based on the patients' menstrual cycle on the admis-
sion day. All participants received COS cycles using GnRH antagonist
for pituitary suppression. No patient in either group had received
chemotherapy or radiotherapy before undergoing COS cycles.
Controlled ovarian stimulation protocols
Conventional COS or random start COS protocol were offered to the
patients based on their menstrual cycle day, the start dose and adjust-
ment of gonadotropins were based on their body mass index (BMI),
age and ovarian reserve. Ovarian reservewas estimated by antral follicle
count (AFC), anti-Mullerian hormone (AMH) and FSH when available.
Patients received daily doses of Gonal F (Serono Laboratories Ltd,
Geneva, Switzerland), while being monitored by vaginal ultrasound.
The gonadotropin dose was adjusted according to the size and the
number of developing follicles. Patients in the conventional-start
group received ovarian stimulation on day two or three of their men-
strual cycles; when the lead follicle measured ≥14 mm, GnRH antago-
nist 0.25 mg (Cetrotide, EMD-Serono) was administered to preventthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 2
Comparison of the cycle characteristics of patients undergoing conventional- or random-
start controlled ovarian stimulation cycles for fertility preservation.





Age of patients (years) 29.1 ± 4.8 28.1 ± 2.5 0.6
BMI 25.7 ± 4.3 23.2 ± 2.5 0.2
AMHa 1.7 ± 1.1 1.7 ± 1.7
Cancer type n (%) Ovarian cancer 5 (71.4) 5 (71.4) 0.5
Uterine cancer 1 (14.3) 2 (28.6)
Breast cancer 1 0
Previous live birth 2 (28.6) 3 (42.9) 0.5
Infertility + 4 (66.7) 2 (40) 0.4
Infertility duration 3.2 ± 1.8 3.0 ± 0.0 0.8
Type of infertility
Cause of infertility n (%) Male 1 (25) – 0.2
PCOS 2 (50) –
Unexplained 1 (25) 2 (100)
Days of ovarian stimulation (SD) 7.8 ± 1.0 8.7 ± 2.0 0.3
Start dose of gonadotropins (IU) 257.1 ± 95.4 235.7 ± 51.7 0.6
Total dose of gonadotropins (IU) 2153 ± 850 2100 ± 806 0.9
No. of follicles ≥12 mm 9.8 ± 5.1 10.7 ± 7.6 0.8
No. of oocytes retrieved 5.8 ± 3.9 7.8 ± 0.0 0.5
No. of MIIb oocytes 5.2 ± 3.6 7.2 ± 6.6 0.5
No. of MII oocytes/oocytes retrieved 0.96 ± 0.06 0.92 ± 0.13 0.5
Fertilization rate 0.60 ± 0.34 0.74 ± 0.25 0.4
No. of embryos 3.6 ± 2.3 6.0 ± 6.3 0.4
No of freezed embryos 3.5 ± 2.3 7.2 ± 6.3 0.2
Data are presented as means ± SD and number %.
a Anti-Mullerian hormone.
b Metaphase II.
20 B.H. Rashidi et al. / Gynecologic Oncology Reports 10 (2014) 19–21premature ovulation, and daily injection was continued until at least
two follicles ≥18 mm were detected. Ovulation induction was per-
formed by using human chorionic gonadotropin (Pregnyl®; Darou
Pakhsh Pharmaceutical, Tehran-Iran) 10,000 IU, intramuscularly.
The random start group patients received COS irrespective of their
menstrual cycle (from days 4 to 23). Ovarian stimulation without pre-
administration of GnRH antagonist was proceeded; when the follicle
cohort after stimulation reached 12 mm, to eliminate premature LH
surge, GnRH antagonist was then initiated and continued until trigger-
ing ﬁnal oocyte maturation with hCG. Only in one patient in random-
start group, ﬁnal oocyte maturation was triggered with GnRH agonist
(subcutaneous injection of 500 μg busereline (Superfact; Aventis
Pharma Deutshlan, Frankfurt, Germany) to reduce the risk of OHSS.
In both groups oocyte retrieval followed 34–36 h after ﬁnal oocyte
maturation. Intra-cytoplasmic sperm injection (ICSI) was undertaken
in all patients to mitigate fertilization failures. For embryo banking
only metaphase II (MII) oocytes were fertilized by ICSI. Embryos were
cryopreserved on either day 3 or day 5.
Outcome measures
Our main outcome measure was the number of mature (MII)
oocytes retrieved in both groups. Secondary outcome measures were
total dosage of gonadotropins, number of days needed for ovarian
stimulation, total number of oocytes retrieved, oocyte maturity rate
(MII oocytes/total oocytes), and fertilization rate (percentage of 2PN
stage/total injected oocytes).
Results
During the study period, 10 patients with ovarian cancer, three
patientswith uterine cancer and one patientwith breast cancerwere re-
ferred to our centers for fertility preservation. Seven patients underwent
conventional-start and seven with random-start COS. Oocyte cryopres-
ervation was performed in one patient (14%) in each group (one patient
was not married, and the husband of the other one could not obtain
semen for injection) and embryo cryopreservation was done in six
patients (86%) in conventional-start group and also ﬁve patients (71%)
in random start group. One patient with random start group did not
have any embryo to freeze. Baseline and cycle characteristics of study
cases were presented in Table 1.
Table 2 shows demographic characteristics of patients in the two
groups according to conventional-start or random-start COS. The differ-
ences between the two groups regarding age, body mass index (BMI),
AMH, cancer type, pregnancy history, and infertility history were notTable 1
Baseline characteristics of study cases.






1 29 Cervical cancer Yes Yes Secondary
2 32 Submucous leiomyosarcoma No No –
3 26 Borderline ovarian papillary serous tumor Yes Yes –
4 24 Borderline ovarian papillary serous tumor Yes Yes –
5 37 Breast cancer No No Primary
6 32 Borderline ovarian papillary serous tumor No No Primary
7 24 Endometrioid and mucinous ovarian
carcinoma
No No Primary
8 29 Borderline ovarian papillary serous tumor
and endometrioid carcinoma
No No Primary
9 32 Borderline ovarian papillary serous tumor Yes Yes Secondary
10 29 Ovarian serous carcinoma No No –
11 26 Borderline ovarian papillary serous tumor Yes Yes –
12 26 Endometrial adenocarcinoma No No –
13 30 Ovarian papillary serous adenocarcinoma No No Primary
14 25 Ovarian papillary serous adenocarcinoma No No –signiﬁcant. Fortunately we did not have any cancelation cycle due to
no ovarian response. In the random start group one patient had no fer-
tilized oocyte after ICSI. Ovarian stimulationwas started in late follicular
phase (days 8–13 of menstrual cycle) in one patient and in luteal phase
(≥14 day of menstrual cycle) in three patients. No differences were ob-
served in total dose of gonadotropins (P= 0.9). In both groups, the du-
ration of gonadotropin administration was slightly but not signiﬁcantly
higher in the random-start group (7.8±1.0 vs. 8.7±2.0 days, P= 0.3).
Themean number of oocytes retrieved, metaphase II (MII) oocytes, was
slightly but not signiﬁcantly higher in the random-start group (7.8±0.0
and 7.2 ± 6.6) vs. (5.8 ± 3.9 and 5.2 ± 3.6), P = 0.5. However oocyte
maturity rates (MII oocytes/total oocytes) were similar between the
groups (0.92 ± 0.13 vs. 0.96 ± 0.06). Fertilization rates per MII oocyte












21 3300 11 23 20 17 17 embryos
16 2700 9 7 6 4 4 embryos
23 2250 10 1 1 0 –
1 1800 8 4 3 3 3 embryos
3 1800 6 10 7 4 3 embryos
3 2025 9 1 1 1 1 embryo
2 1575 7 12 12 8 8 embryos
3 1800 8 4 3 3 3 embryos
3 4050 9 3 3 3 3 embryos
5 1125 5 2 2 2 2 embryos
4 1050 7 6 6 3 3 embryos
2 2025 8 7 7 – 7 oocytes
4 2250 10 4 4 4 4 oocytes
8 2025 9 12 12 10 10 embryos
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In this prospective, case series study, we evaluated the outcomes of
the emergency fertility preservation protocol (random start) in cancer
patients including ovarian tumor.
All cancer patients of reproductive age (or younger) must be
informed and discussed about fertility issues associated with their
cancer and foreseen treatments. However the role of conservative treat-
ment, that is aimed at preserving subsequent fertility with borderline
ovarian tumor, has gained considerable attention during the last decade
(Morice, 2006). The management of such cases has been a matter of
controversy. Particularly based on initial publications that theoretically
contraindicated infertility treatment in patients who were treated for
ovarian malignancies. Fortunately, these data have not been conﬁrmed
andnewer data are quite reassuring (Fortin et al., 2007; Fasouliotis et al.,
2004).
The choice of the speciﬁc COS protocol is inﬂuenced by the available
time until the initiation of cancer therapy. There is emerging evidence
that oocytes can be obtained before cancer treatment efﬁciently,
irrespective of the phase of themenstrual cycle (VonWolff et al., 2009).
Evidence to support the hypothesis of efﬁcacy of random start COS is
ovarian physiology. The time that takes in progressing from a primary
follicle to ovulation is about 85 days (Gougeon, 1986). The late stage
of this development is dependent on hormonal regulation. Where,
without rescue by follicle-stimulating hormone (FSH), atresia will
occur (Oktay et al., 1998).
Administration of GnRH antagonists in luteal phase has been used to
reduce time frame for cancer patients.
In a study by Anderson et.al corpus luteum breakdown was induced
by GnRH antagonists during the preceding luteal phase, resulting in a
rapid fall of progesterone. COS stimulationwas followed 4 days after ad-
ministration of GnRH antagonists. Eight and 6 oocytes were retrieved,
and then 6 and 4 mature oocytes were successfully fertilized by IVF
(Anderson et al., 1999).
In a pilot study by Von wolf, no time was left for luteolysis before
starting ovarian stimulation by recombinant FSH after administration
of GnRH antagonists, and combination of both medications was contin-
ued to ovulation induction time. In comparison with stimulation in the
follicular phase group, both groups had a similar number of retrieved
oocytes and MII oocytes as well as similar fertilization rates. They con-
clude that high progesterone concentrations at the beginning of ovarian
stimulation in the luteal phase group did not affect oocyte quality (Von
Wolff et al., 2009).
In another study by Cakmak et al., women diagnosed with cancer
were stimulated on presentation regardless of their menstrual-cycle
day (Cakmak et al., 2013).
In our study, one patient was in the late follicular phase (days 8–13)
and GnRH antagonist was started when the secondary follicle cohort
following stimulation reached 12 mm, after induction of ovulation, 12
metaphase II (MII) oocytes were collected, and 8 oocytes were success-
fully fertilized by ICSI, resulting in a fertilization rate of 66.6%, which
shows similar results to Cakmak and Rosen (2013) study.
GnRH antagonist administration could be initiated later in the cycle,
when the follicle cohort (has) reached 12 mm to precede fertilitypreservation without compromising oocyte yield and maturity. The
concept of our protocol for the patients in luteal phase differs from the
described protocol suggested by von wolf, but is in concordance with
the study conducted by Cakmak et al. (2013) and Von Wolff et al.
(2009). In our study COS without GnRH antagonist was started. Similar
to conventional antagonist protocol, when the follicle reached 12 mm,
GnRH antagonist was initiated and continued until ﬁnal oocyte
maturation.
In summary, GnRH antagonist administration could be initiated
at any time, to prevent premature LH surge and would continue until
the ﬁnal oocyte maturation. This approach decreases total time for the
IVF cycle in urgent settings without compromising oocyte yield and
maturity.Conclusion
According to our preliminary report, considering the limitation of
the sample size, the promising results should encourage oncologists
for early referral of women with different types of cancer to fertility
specialists for emergency fertility preservation. In addition, this method
may prevent delay in cancer treatment.Conﬂict of interest statement
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